11.2 Neurogenic Bladder & Bowel Management

Neurogenic Bladder Pathophysiology & Urodynamic Concepts

Neurogenic bladder dysfunction is categorized based on the level of neurological lesion relative to the major micturition control centers: the Pontine Micturition Center (PMC), the Thoracolumbar Sympathetic Center (T11–L2), and the Sacral Parasympathetic / Somatic Center (S2–S4).

Suprasacral (Upper Motor Neuron - UMN) Lesions

• Location: Spinal cord lesions above the sacral micturition center (above T12/L1 level).
• Bladder Phenotype: Detrusor Hyperreflexia / Overactivity with or without Detrusor Sphincter Dyssynergia (DSD).
• Pathophysiology: Disruption of descending reticulospinal pathways isolates the sacral reflex arc from cortical and pontine inhibitory control. The detrusor muscle contracts involuntarily at low filling volumes.
• Detrusor Sphincter Dyssynergia (DSD): Involuntary, discoordinated contraction of the striated external urethral sphincter (pudendal nerve, S2–S4) occurring simultaneously with detrusor contraction. DSD acts as a functional bladder outlet obstruction, generating markedly elevated intravesical pressures during micturition.
• Complications: High storage and voiding pressures ($>40 ext{ cm H}_2 ext{O}$) can lead to vesicoureteral reflux (VUR), hydronephrosis, renal scarring, pyelonephritis, and progressive renal failure. In lesions at or above T6, DSD and bladder distension are classic triggers for autonomic dysreflexia (AD).

Sacral and Infrasacral (Lower Motor Neuron - LMN) Lesions

• Location: Lesions involving the sacral micturition center (conus medullaris, S2–S4), cauda equina, or peripheral pelvic nerves.
• Bladder Phenotype: Detrusor Areflexia / Acontractility (flaccid bladder) with intact or impaired sphincter tone.
• Pathophysiology: Interruption of the sacral parasympathetic reflex arc (pelvic splanchnic nerves, S2–S4) abolishes detrusor contractility. The bladder fills passively to large capacities without sensation or contraction.
• Complications: Markedly elevated post-void residual (PVR) volumes, chronic bladder overdistension, detrusor muscle overstretching, urinary tract infections (UTIs), and overflow incontinence.

Urodynamic Study (UDS) Parameters

Urodynamics is the definitive diagnostic modality for evaluating lower urinary tract function in rehabilitation:

• Bladder Compliance ($\Delta V / \Delta P$): Change in volume divided by change in detrusor pressure during filling. Normal compliance is $>30 ext{ mL/cm H}_2 ext{O}$. Low compliance ($<10 ext{–}12 ext{ mL/cm H}_2 ext{O}$) reflects rigid, non-compliant bladder walls and high risk for upper tract deterioration.
• Detrusor Leak Point Pressure (DLPP): The lowest detrusor pressure at which urine leakage occurs around the catheter in the absence of abdominal straining or detrusor contraction. DLPP $>40 ext{ cm H}_2 ext{O}$ is a critical risk threshold strongly correlated with upper urinary tract damage and hydronephrosis.
• Maximum Cystometric Capacity (MCC): The bladder volume at which the patient experiences an uncomfortable urge to void or at which filling is halted (normal adult MCC: 350–500 mL).

---

Clean Intermittent Catheterization (CIC)

Clean Intermittent Catheterization (CIC) is the gold standard for neurogenic bladder emptying in individuals with UMN or LMN neurogenic bladder who possess adequate hand function or have dedicated caregiver support.

---

Pharmacotherapy & Interventional Procedures for Neurogenic Bladder

[Neurogenic Bladder Management Flowchart]
                      │
      ┌───────────────┴───────────────┐
      ▼                               ▼
[Detrusor Overactivity (UMN)]   [Detrusor Areflexia (LMN)]
      │                               │
  First Line:                     First Line:
  • CIC q4-6h (Vol <400-500mL)    • Timed CIC q4-6h
  • Anticholinergics (Oxybutynin) • Valsalva/Credé (Caution)
  • Beta-3 Agonist (Mirabegron)       │
      │                           Refractory:
  Refractory:                     • Alpha-blockers
  • Intravesical Botox 200U       • Surgical Diversion

1. Anticholinergic / Antimuscarinic Medications:
   • Agents: Oxybutynin (oral/transdermal), Tolterodine, Solifenacin, Darifenacin.
   • Mechanism of Action: Competitive antagonist of muscarinic acetylcholine receptors (M2 and M3) on detrusor smooth muscle. Inhibits uninhibited detrusor contractions, increases maximum cystometric capacity, and lowers storage pressures.
   • Side Effects: Dry mouth (xerostomia), constipation, blurred vision (mydriasis), tachycardia, urinary retention, and cognitive impairment / central nervous system effects (especially in elderly patients or those with TBI, mediated by crossing the blood-brain barrier).
2. Beta-3 Adrenergic Agonists:
   • Agents: Mirabegron, Vibegron.
   • Mechanism of Action: Selective agonist of beta-3 adrenergic receptors in detrusor muscle. Stimulates detrusor relaxation during the storage phase, enhancing bladder compliance and capacity without anticholinergic side effects.
   • Clinical Utility: Excellent alternative or add-on therapy for patients unable to tolerate antimuscarinics. Precaution: Mirabegron can elevate blood pressure; monitor in patients with uncontrolled hypertension.
3. Intravesical OnabotulinumtoxinA (Botox):
   • Indication: Neurogenic detrusor overactivity refractory to oral pharmacotherapy.
   • Mechanism of Action: Injected cytoscopically into the detrusor muscle (typically 200 units across 20–30 sites, sparing the trigone). Botox cleaves SNAP-25, inhibiting presynaptic acetylcholine release at the neuromuscular junction.
   • Efficacy & Duration: Reduces intravesical pressure and incontinence episodes for 6 to 9 months.
   • Adverse Effect: Transient urinary retention requiring CIC, and increased incidence of UTIs.

---

Neurogenic Bowel Management: UMN vs. LMN

Neurogenic bowel dysfunction following neurological injury is categorized into Upper Motor Neuron (UMN) bowel and Lower Motor Neuron (LMN) bowel based on the preservation of the sacral reflex arc (S2–S4).

Pharmacological Bowel Regimen Agents

• Stool Softeners: Docusate sodium (emulsifies water and fat into stool; ineffective as monotherapy).
• Osmotic Laxatives: Polyethylene glycol (PEG 3350 / Miralax), Lactulose, Magnesium hydroxide. Draws water into the bowel lumen to increase stool bulk and softness.
• Stimulant Laxatives: Bisacodyl (oral or rectal suppository), Senna. Direct chemical stimulation of the myenteric plexus to induce colonic peristalsis. Rectal bisacodyl works within 15–30 minutes to initiate a UMN bowel program.
• Prokinetics: Metoclopramide, Prucalopride (selective 5-HT4 agonist). Enhances gastrointestinal motility in severe slow-transit constipation.